All Posts By

Smartkarma Newswire

US Market Movers Today – 19 February 2025

By | Market Movers

Biggest stock gainers today in S&P 500

CompanyStock PricePercentage ChangeSmartkarma SmartScore
Garmin Ltd. (GRMN)241.93 USD+12.64%3.8
Microchip Technology Incorporated (MCHP)63.59 USD+9.90%3.2
Analog Devices, Inc. (ADI)241.66 USD+9.74%3.2
Super Micro Computer, Inc. (SMCI)60.25 USD+7.97%3.4
Devon Energy Corporation (DVN)37.57 USD+7.71%3.2
NXP Semiconductors N.V. (NXPI)245.58 USD+7.31%4.0
Charles River Laboratories International, Inc. (CRL)165.00 USD+6.87%2.8
ON Semiconductor Corporation (ON)55.52 USD+6.87%2.8
Molina Healthcare, Inc. (MOH)286.79 USD+6.79%3.0
Texas Instruments Incorporated (TXN)196.32 USD+5.29%3.4

Biggest stock losers today in S&P 500

CompanyStock PricePercentage ChangeSmartkarma SmartScore
Celanese Corporation (CE)54.91 USD-21.46%3.2
Axon Enterprise, Inc. (AXON)593.42 USD-16.42%3.4
Palantir Technologies Inc. (PLTR)109.08 USD-12.47%3.4
Cadence Design Systems, Inc. (CDNS)274.04 USD-8.78%2.6
Arista Networks Inc (ANET)103.92 USD-6.43%3.4
Intel Corporation (INTC)25.72 USD-6.10%3.8
International Flavors & Fragrances Inc. (IFF)81.99 USD-5.16%3.0
Synopsys, Inc. (SNPS)500.98 USD-4.58%3.0
West Pharmaceutical Services, Inc. (WST)202.49 USD-4.03%3.0
Caesars Entertainment, Inc. (CZR)37.97 USD-3.95%3.0

What is Smartkarma SmartScore?

It is a compound score for a Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores (Value, Dividend, Growth, Resilience, Momentum scores) computed by Smartkarma.

The best stock screener – Smartkarma SmartScore Screener

Smartkarma’s stock screener, Smartkarma SmartScore Screener, allows you to easily discover undervalued gems, high dividend stocks, and high growth stocks, across multiple countries and sectors.

Explore the Smartkarma SmartScore Screener now.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Microchip Technology Incorporated’s stock price soars to $63.59, marking a stunning 9.90% increase

By | Market Movers

Microchip Technology Incorporated (MCHP)

63.59 USD +5.73 (+9.90%) Volume: 20.79M

Microchip Technology Incorporated’s stock price soared to $63.59, marking a significant trading session increase of +9.90%. With a robust trading volume of 20.79M shares, MCHP’s stock has shown a promising YTD growth of +10.11%, making it a compelling choice for investors seeking steady returns.


Latest developments on Microchip Technology Incorporated

Microchip Technology‘s stock price surged by 10% following the release of their AI-powered MPLAB Coding Assistant, aimed at streamlining embedded software development. The company’s latest innovation combines artificial intelligence with embedded development, promising to enhance software development with AI tools. Despite the positive news, investors are advised to conduct thorough research before buying Microchip’s stock, especially with the upcoming dividend. The release of the AI Coding Assistant has generated significant interest in the tech community, with questions arising about its potential to transform embedded systems development. Microchip’s strategic move towards integrating AI into their products has attracted the attention of investors, including Bank of Jackson Hole Trust, who recently acquired over 8,000 shares of Microchip Technology Incorporated (NASDAQ:MCHP).


Microchip Technology Incorporated on Smartkarma

Analysts on Smartkarma have been closely monitoring Microchip Technology, with insights from providers like Baptista Research and William Mann. Baptista Research highlighted the challenges faced by Microchip in its Q3 Fiscal 2025 results, where the company reported a significant decline in net sales due to weak demand across all major geographies and product categories. The company is now focused on implementing a strategic plan to restructure its operations and improve performance. On the other hand, William Mann expressed a bearish sentiment on the company, citing declining fundamentals, high valuation, geo-political risks, and operational challenges that could lead to a sharp correction in the stock price if sector rotation occurs.

With conflicting views from analysts, investors are faced with a decision on the future of Microchip Technology. While Baptista Research points out the challenges ahead for the company and its efforts to overcome them, William Mann’s bearish outlook raises concerns about declining fundamentals and potential risks. As Microchip navigates through a challenging business environment, investors will be closely watching for any developments that could impact the company’s performance and stock price in the coming months.


A look at Microchip Technology Incorporated Smart Scores

FactorScoreMagnitude
Value3
Dividend5
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Microchip Technology has a solid overall outlook according to Smartkarma Smart Scores. With a high score in Dividend and moderate scores in Value, Growth, and Momentum, the company seems to be in a good position for the long term. However, its lower score in Resilience may indicate some potential risks that investors should be aware of.

Microchip Technology is a company that designs, manufactures, and markets microcontrollers and related products for embedded control applications. With a strong focus on dividends and a decent performance in growth and momentum, the company shows promise for the future. Despite facing some challenges in terms of resilience, Microchip Technology‘s overall outlook remains positive based on the Smartkarma Smart Scores.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Biomarin Pharmaceutical (BMRN) Earnings Soar: Q4 Adjusted EPS Surpasses Estimates with Strong Revenue Growth

By | Earnings Alerts
  • BioMarin’s 4th Quarter Adjusted Earnings Per Share (EPS) surpassed expectations with 92 cents compared to the previous year’s 49 cents, and an estimate of 73 cents.
  • The company’s EPS for the quarter was 64 cents, significantly up from 11 cents year-over-year, beating the estimate of 52 cents.
  • Total revenue for the quarter reached $747 million, marking a 16% increase from the previous year and exceeding the projected $712.5 million.
  • Naglazyme, one of the revenue driving products, reported $110 million, rising by 12% year-over-year, albeit slightly below the estimate of $112.6 million.
  • Voxzogo revenue rose sharply by 43% to $208 million, exceeding the forecast of $204 million. This product is poised for a compound annual growth rate (CAGR) exceeding 25% from 2023 to 2027.
  • BioMarin projects double-digit revenue increases for PALYNZIQ throughout 2024, with consistent growth expected for other enzyme treatments into 2025.
  • The Skeletal Conditions business unit is expected to experience strong growth in 2025, driven largely by the global expansion of VOXZOGO for achondroplasia.
  • The market analysts’ sentiment remains positive with 22 buy recommendations, 7 holds, and no sell recommendations.

Biomarin Pharmaceutical on Smartkarma

Analysts on Smartkarma, like Baptista Research, are closely examining Biomarin Pharmaceutical’s latest developments. In a bullish report titled “BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio,” the company’s strong performance in the third quarter of 2024 takes the spotlight. With a noteworthy 28% year-on-year revenue growth to $746 million, Biomarin has set a new record. The surge in sales of VOXZOGO, a treatment for achondroplasia, played a significant role in this success, propelled by increased market penetration in the U.S. and expansions into new regions.


A look at Biomarin Pharmaceutical Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth5
Resilience4
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Looking at the Smartkarma Smart Scores for Biomarin Pharmaceutical, the company seems to have a promising long-term outlook. With a high Growth score and solid Resilience score, Biomarin Pharmaceutical appears well-positioned for future success. The company’s focus on developing therapeutic enzyme products for various medical conditions, including lysosomal storage diseases and serious burns, highlights its commitment to innovation and addressing unmet medical needs.

Although Biomarin Pharmaceutical may not rank as high in terms of Value and Dividend scores, its strong performance in Growth and Resilience indicates potential for continued expansion and durability in the market. Investors looking for a company with a focus on cutting-edge treatments and a solid foundation for growth may find Biomarin Pharmaceutical an appealing choice for long-term investment.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

IMAX Corp (IMAX) Earnings: 4Q Revenue Falls Short of Estimates Despite Growth in Adjusted Earnings and Margins

By | Earnings Alerts
  • Imax reported a revenue of $92.7 million in Q4, showing a 7.7% increase year-over-year, but it fell short of the $101.4 million estimate.
  • Content solutions revenue reached $25.5 million, marking a 34% increase from the previous year and just under the $25.8 million estimate.
  • Technology products and services revenue was $64.0 million, up 2.5% year-over-year, but below the $73.6 million forecast.
  • The company’s gross margin improved to 52.2%, compared to 51% last year, but did not meet the 56.4% estimate.
  • Adjusted EPS was 27 cents, meeting the estimate and showing an increase from 17 cents in the previous year.
  • Adjusted net income was $14.5 million, an impressive 56% increase year-over-year, but short of the $16.4 million estimate.
  • Adjusted EBITDA per credit facility was $34.2 million, falling below the expected $36.9 million.
  • The adjusted EBITDA margin improved significantly to 40.1%, from 29% last year, surpassing the 34.7% estimate.
  • Income from operations rose to $9.51 million, compared to $2.74 million in the previous year, but was less than the $19.2 million estimate.
  • The total number of commercial multiplex theaters increased by 2.5% year-over-year to 1,735, slightly under the estimated 1,767.
  • Cash and cash equivalents rose by 32% from the previous year to $100.6 million, just shy of the $101.2 million estimate.
  • Analyst ratings include 8 buys, 1 hold, and 1 sell recommendation for the company.

A look at IMAX Corp Smart Scores

FactorScoreMagnitude
Value2
Dividend1
Growth4
Resilience2
Momentum5
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

IMAX Corp, a company known for its cutting-edge cinematic solutions, has a promising long-term outlook based on its Smartkarma Smart Scores. With a strong Growth score of 4 and Momentum score of 5, IMAX is positioned well for future expansion and market performance. The company’s focus on technological advancement and innovative film formats sets a solid foundation for sustained growth in the entertainment industry.

Despite lower scores in Value and Dividend at 2 and 1 respectively, IMAX’s resilience score of 2 indicates its ability to weather challenges and adapt to changing market conditions. This, combined with its impressive Growth and Momentum scores, suggests that IMAX Corp has the potential to remain a key player in the cinematic industry over the long term, continuing to provide audiences with enhanced movie experiences.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

ANZ Group Holdings (ANZ) Earnings: 1Q Report Reveals 11.5% Common Equity Tier 1 Ratio Amidst Credit Risk Asset Increase

By | Earnings Alerts
“`html

  • ANZ Group reported a Common Equity Tier 1 (CET1) ratio of 11.5% for the first quarter.
  • The CET1 ratio is a key measure of a bank’s financial strength, reflecting the capital it holds as a percentage of its risk-weighted assets.
  • ANZ’s Credit Risk Weighted Assets were valued at A$379.4 billion as of December 31.
  • There was an increase in Credit Risk Weighted Assets by A$18.2 billion from the previous quarter.
  • Investment analysts have varying recommendations on ANZ Group: 3 analysts recommend buying, 9 recommend holding, and 4 recommend selling.

“`


ANZ Group Holdings on Smartkarma

Analysts on Smartkarma, such as Gaudenz Schneider, are closely covering ANZ Group Holdings. Gaudenz Schneider‘s recent report titled “EQD | ANZ Group Holdings (ANZ AU): Anticipated Price Swings on Q1 Announcement on 20 Feb 2025″ sheds light on the upcoming First Quarter APS 330 release by ANZ Group Holdings on 20 February 2025. The report suggests that traders can utilize listed options to gauge option-implied price swings and potentially capitalize on the event. Notably, historical data indicates an average price movement of 1.9% for ANZ after profit announcements, with option markets foreseeing a similar trend this time.

This insightful analysis by Gaudenz Schneider provides traders with strategies to navigate the market reactions post the First Quarter APS 330 release. The report emphasizes the risk implications associated with different market expectations and aims to assist traders in making well-informed decisions. Analyst coverage on Smartkarma offers valuable insights into ANZ Group Holdings, equipping investors with crucial information to optimize their trading strategies and potentially benefit from anticipated price movements surrounding the Q1 announcement on 20 February 2025.


A look at ANZ Group Holdings Smart Scores

FactorScoreMagnitude
Value4
Dividend4
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE3.2

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

ANZ Group Holdings Limited, a banking and financial services company, is positioned with strong scores in value and dividend, both rated at 4 on the Smartkarma Smart Scores. This indicates a solid outlook for the company in terms of its value and dividend-paying potential. However, ANZ Group Holdings received a growth score of 3, signaling moderate growth prospects. In terms of resilience, the company scored a 2, suggesting some susceptibility to market fluctuations. Additionally, the momentum score of 3 indicates a steady performance trend for the company.

ANZ Group Holdings Limited, a holding company offering banking and financial services, has received a mixed outlook based on the Smartkarma Smart Scores. While the company fares well in terms of value and dividend, with scores of 4, suggesting strong fundamentals in these areas, the growth score of 3 reflects moderate growth prospects. However, with a resilience score of 2, ANZ Group Holdings may face some challenges in navigating market uncertainties. The momentum score of 3 hints at a stable performance trend for the company moving forward.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

TFI International (TFII) Earnings: Q4 Adjusted EPS Falls Short of Estimates with Mixed Revenue Performance

By | Earnings Alerts
  • TFI International’s adjusted earnings per share (EPS) for the fourth quarter was $1.19, missing the estimate of $1.58 and decreasing from $1.71 year-over-year (y/y).
  • The company’s overall revenue for the quarter was reported at $2.08 billion, representing a 5.5% increase y/y, but fell short of the estimated $2.18 billion.
  • Truckload revenue significantly increased by 74% y/y, reaching $693.2 million.
  • Logistics revenue decreased by 13% y/y, amounting to $410.2 million.
  • LTL (Less-than-Truckload) revenue rose by 5.9% y/y, totaling $737.3 million.
  • Operating income stood at $160.2 million, down by 19% y/y, missing the estimate of $203.9 million.
  • Adjusted EBITDA dropped by 1.7% y/y, reported at $315.3 million, compared to the estimate of $352.8 million.
  • The adjusted net income saw a 31% decline y/y, coming in at $101.8 million, falling short of the estimated $135.1 million.
  • The market analyst consensus shows 14 buy ratings, 5 hold ratings, and no sell ratings for TFI International.

A look at Tfi International Smart Scores

FactorScoreMagnitude
Value3
Dividend2
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

TFI International Inc, a key player in the transportation and logistics sector, is poised for a steady long-term outlook. With a balanced mix of moderate scores across various key factors, the company signals potential for sustained growth and resilience in the market. Notably, TFI International’s Smartkarma Smart Scores indicate a solid position in terms of value, growth, and momentum, reflecting a promising trajectory for the company’s performance.

Primarily specializing in strategic acquisitions and overseeing a network of subsidiaries, TFI International operates extensively in the United States, Canada, and Mexico. The company’s consistent scores in value, growth, and momentum underscore its competitive position and resilience in the evolving market landscape, highlighting a positive long-term outlook for investors looking towards stable returns in the transportation and logistics industry.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Wesfarmers Ltd (WES) Earnings: 1H Net Income Meets Estimates with Strong Bunnings Revenue Performance

By | Earnings Alerts
  • Wesfarmers reported a net income of A$1.47 billion, closely matching the estimate of A$1.48 billion.
  • The interim dividend per share was A$0.95, aligning with market expectations.
  • Bunnings exceeded revenue forecasts with A$10.28 billion, surpassing the estimate of A$9.86 billion.
  • Kmart group’s revenue came in slightly below expectations at A$6.11 billion, versus the estimate of A$6.16 billion.
  • Officeworks reported revenue of A$1.76 billion, slightly above the expected A$1.73 billion.
  • The Chemicals, Energy & Fertilizers division generated A$1.21 billion in revenue, narrowly missing the A$1.22 billion estimate.
  • The Industrial & Safety division’s revenue was A$990 million, falling short of the A$1.01 billion estimate.
  • Health segment revenue was A$3.02 billion, just under the estimated A$3.03 billion.
  • Market analyst ratings included 2 buys, 5 holds, and 9 sells.

A look at Wesfarmers Ltd Smart Scores

FactorScoreMagnitude
Value2
Dividend3
Growth3
Resilience2
Momentum4
OVERALL SMART SCORE2.8

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Wesfarmers Ltd., a diversified conglomerate with interests spanning retail, mining, insurance, manufacturing, and distribution, showcases a promising long-term outlook as per the Smartkarma Smart Scores. With a strong momentum score of 4, indicating positive price trends and market sentiment, the company is positioned well for potential growth. Additionally, Wesfarmers scores well on dividend and growth factors, garnering scores of 3 on both aspects, reflecting a solid financial foundation and growth prospects.

While the company’s value and resilience scores are slightly lower at 2, Wesfarmers maintains a balanced approach across its various business segments. This mix of factors suggests a favorable overall outlook for Wesfarmers Ltd., portraying a company with potential for continued growth and stability in the long term.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Exact Sciences (EXAS) Earnings: 2025 Revenue Forecast and Q4 Results Unveiled

By | Earnings Alerts
  • Exact Sciences projects 2025 revenue between $3.03 billion and $3.09 billion, with an estimate at $3.06 billion.
  • Projected Screening revenue is between $2.35 billion and $2.39 billion, estimated at $2.37 billion.
  • Precision Oncology revenue is forecasted to be between $675 million and $695 million, with an estimate of $687.3 million.
  • Fourth-quarter results showed a loss per share of $4.67, compared to a previous year’s loss per share of 27 cents, with an estimated loss per share of 34 cents.
  • Quarterly revenue increased by 10% year-over-year to $713.4 million, surpassing the estimated $701 million.
  • Screening revenue rose 14% year-over-year to $553.0 million, exceeding the estimated $541.7 million.
  • Precision Oncology revenue slightly increased by 0.5% year-over-year to $161.0 million, above the estimate of $159.8 million.
  • Adjusted EBITDA saw a 52% year-over-year increase to $75.4 million, beating the estimated $67.6 million.
  • The company plans to launch three new cancer tests in 2025: Cologuard Plusâ„¢, Oncodetectâ„¢, and Cancerguardâ„¢.
  • Exact Sciences currently has 24 buy and 2 hold recommendations, with zero sell recommendations.

Exact Sciences on Smartkarma

Analyst coverage on Smartkarma by Baptista Research delves into Exact Sciences Corporation’s recent performance in the third quarter of 2024. The report highlights a mix of achievements and challenges faced by the company, showcasing a positive financial trajectory. Exact Sciences saw a 13% year-over-year surge in total revenue to $709 million, propelled by the increasing adoption of Cologuard and the international expansion of Oncotype DX. Furthermore, a noteworthy 75% uptick in adjusted EBITDA to $99 million and a record free cash flow of $113 million underscore the company’s significant strides in enhancing operational efficiency.


A look at Exact Sciences Smart Scores

FactorScoreMagnitude
Value3
Dividend1
Growth4
Resilience3
Momentum2
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Exact Sciences Corp., focused on developing a non-invasive molecular screening test for early detection and prevention of colorectal cancer, shows a promising long-term outlook based on its Smartkarma Smart Scores. With a high Growth score of 4, the company is positioned well for future expansion and development in the field of cancer screening. Additionally, a Resilience score of 3 indicates the company’s ability to withstand market challenges and maintain its performance.

However, Exact Sciences has lower scores in other areas such as Dividend and Momentum, which may pose challenges in terms of investor attractiveness and short-term performance. Despite this, the company’s overall outlook remains positive, with a Value score of 3 suggesting a fair valuation in the market. Investors may find potential in Exact Sciences for long-term growth and innovation in the fight against colorectal cancer.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Churchill Downs (CHDN) Earnings: Q4 Adjusted EPS Falls Short Despite Revenue Increase

By | Earnings Alerts
  • Churchill Downs reported an adjusted EPS of $0.92, which was below the estimated $0.94.
  • The company’s EPS increased to $0.95 from $0.76 compared to the same quarter last year.
  • Net revenue reached $624.2 million, marking an 11% growth year-over-year, slightly surpassing the estimate of $620.2 million.
  • Adjusted net income was reported at $68.7 million, up 5% from the previous year, but slightly below the expected $69.7 million.
  • The company’s stock received 10 buy ratings, 1 hold rating, and no sell ratings.

A look at Churchill Downs Smart Scores

FactorScoreMagnitude
Value2
Dividend2
Growth4
Resilience2
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Churchill Downs Incorporated, the renowned horse racing company famous for hosting the prestigious Kentucky Derby, shows a promising long-term outlook based on the Smartkarma Smart Scores. With a strong Growth score of 4, the company demonstrates potential for expansion and development in the future. Along with a Momentum score of 3, indicating positive market trends, Churchill Downs is positioned well for continued success.

Although the Value and Dividend scores are average at 2, the company’s resilience, with a score of 2, suggests stability in the face of challenges. Overall, Churchill Downs presents a favorable outlook for investors seeking growth opportunities in the horse racing industry, backed by its strong Growth and Momentum scores.

Summary: Churchill Downs Incorporated is a horse racing company known for hosting the Kentucky Derby. With operations across multiple states and interests in various racing services companies, the company enjoys a strong Growth score and positive Momentum outlook according to Smartkarma Smart Scores.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars

Transurban Group (TCL) Earnings: Revenue Hits A$1.83 Billion with A$0.320 Interim Distribution

By | Earnings Alerts
  • Transurban has announced an interim distribution of A$0.320 per share for the first half of the fiscal year.
  • The company’s revenue for this period stands at A$1.83 billion.
  • Market analysts have varied opinions on Transurban’s stock with 1 analyst recommending a buy, 13 suggesting to hold, and 1 recommending a sell.

A look at Transurban Group Smart Scores

FactorScoreMagnitude
Value2
Dividend4
Growth5
Resilience2
Momentum4
OVERALL SMART SCORE3.4

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Transurban Group, a company that specializes in owning and operating urban toll road networks in Australia and North America, is showing a promising long-term outlook based on the Smartkarma Smart Scores. With an impressive Growth score of 5, Transurban is expected to experience strong expansion in the future, indicating potential for increased profitability and market presence. Additionally, the company’s Dividend score of 4 suggests a solid dividend payout to investors, reflecting financial stability and shareholder-friendly policies. This combination of growth and dividends positions Transurban favorably for investors seeking both capital appreciation and income generation.

However, on the flip side, Transurban’s Value and Resilience scores are more moderate at 2 each, indicating that the company may not be undervalued compared to its peers and might have some vulnerability to economic downturns or industry challenges. Nonetheless, with a Momentum score of 4, suggesting positive stock price trends and market sentiment, Transurban seems to be attracting investor interest and could continue to outperform in the near future. Overall, Transurban’s strong growth prospects and reliable dividend payments paint a positive picture for its long-term performance despite some areas of caution.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars